<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Argent Biopharma Limited — News on 6ix</title>
<link>https://6ix.com/company/argent-biopharma-limited</link>
<description>Latest news and press releases for Argent Biopharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Feb 2026 12:36:05 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/argent-biopharma-limited" rel="self" type="application/rss+xml" />
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/half-yearly-report-and-accounts-519</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/half-yearly-report-and-accounts-519</guid>
<pubDate>Fri, 27 Feb 2026 12:36:05 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>Provisional Patent Lodged with USPTO for NanoBodies Platform</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/provisional-patent-lodged-with-uspto-for-nanobodies-platform</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/provisional-patent-lodged-with-uspto-for-nanobodies-platform</guid>
<pubDate>Wed, 25 Feb 2026 03:49:18 GMT</pubDate>
<description>Provisional Patent Lodged with USPTO for NanoBodies Platform</description>
</item>
<item>
<title>CannEpil - Largest Commercial Shipment Arrives in Ireland</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/cannepil-largest-commercial-shipment-arrives-in-ireland</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/cannepil-largest-commercial-shipment-arrives-in-ireland</guid>
<pubDate>Mon, 23 Feb 2026 03:52:08 GMT</pubDate>
<description>CannEpil - Largest Commercial Shipment Arrives in Ireland</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/quarterly-activitiesappendix-4c-cash-flow-report-272</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/quarterly-activitiesappendix-4c-cash-flow-report-272</guid>
<pubDate>Fri, 30 Jan 2026 02:36:14 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Streamlined Acquisition of AusCann Assets</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/streamlined-acquisition-of-auscann-assets</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/streamlined-acquisition-of-auscann-assets</guid>
<pubDate>Wed, 14 Jan 2026 03:46:04 GMT</pubDate>
<description>Streamlined Acquisition of AusCann Assets</description>
</item>
<item>
<title>A$11m Financing Facility to Complete Strategic Acquisition</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/adollar11m-financing-facility-to-complete-strategic-acquisition</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/adollar11m-financing-facility-to-complete-strategic-acquisition</guid>
<pubDate>Mon, 17 Nov 2025 04:03:10 GMT</pubDate>
<description>A$11m Financing Facility to Complete Strategic Acquisition</description>
</item>
<item>
<title>Appendix 4E and 2025 Annual Report</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/appendix-4e-and-2025-annual-report-52</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/appendix-4e-and-2025-annual-report-52</guid>
<pubDate>Fri, 29 Aug 2025 11:56:14 GMT</pubDate>
<description>Appendix 4E and 2025 Annual Report</description>
</item>
<item>
<title>Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/argent-growing-m-projected-merged-213000011</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/argent-growing-m-projected-merged-213000011</guid>
<pubDate>Wed, 27 Aug 2025 21:30:00 GMT</pubDate>
<description>Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the core assets and IP of AusCann Group Holdings Ltd (AC8). The acquisition includes the Neuvis® patented drug delivery platform, validated FDA-facing epilepsy pre-clinical data supporting CannEpil®, and EU-based commercial infrastructure.</description>
</item>
<item>
<title>U.S. In Vivo Study Supports ArtemiC Efficacy</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/us-in-vivo-study-supports-artemic-efficacy</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/us-in-vivo-study-supports-artemic-efficacy</guid>
<pubDate>Mon, 25 Aug 2025 03:50:20 GMT</pubDate>
<description>U.S. In Vivo Study Supports ArtemiC Efficacy</description>
</item>
<item>
<title>RGT Signs Binding Term Sheet to Acquire AusCann Assets</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/rgt-signs-binding-term-sheet-to-acquire-auscann-assets</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/rgt-signs-binding-term-sheet-to-acquire-auscann-assets</guid>
<pubDate>Tue, 19 Aug 2025 03:56:09 GMT</pubDate>
<description>RGT Signs Binding Term Sheet to Acquire AusCann Assets</description>
</item>
<item>
<title>EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/eu-gmp-cannabinoid-api-supplied-for-epilepsy-in-slovenia</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/eu-gmp-cannabinoid-api-supplied-for-epilepsy-in-slovenia</guid>
<pubDate>Tue, 08 Jul 2025 03:47:11 GMT</pubDate>
<description>EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia</description>
</item>
<item>
<title>Argent BioPharma Enters Germany - Europe's Largest Market</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/argent-biopharma-enters-germany-europes-230000750</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/argent-biopharma-enters-germany-europes-230000750</guid>
<pubDate>Wed, 23 Apr 2025 23:00:00 GMT</pubDate>
<description>Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil® and CogniCann®, following recent regulatory approval. Germany, as the largest healthcare market in Europe, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.</description>
</item>
<item>
<title>Strategic Collaboration Agreement for Malta Facility</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/strategic-collaboration-agreement-for-malta-facility</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/strategic-collaboration-agreement-for-malta-facility</guid>
<pubDate>Wed, 09 Apr 2025 03:30:10 GMT</pubDate>
<description>Strategic Collaboration Agreement for Malta Facility</description>
</item>
<item>
<title>CannEpil Receives Approval for Prescription in Germany</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/cannepil-receives-approval-for-prescription-in-germany</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/cannepil-receives-approval-for-prescription-in-germany</guid>
<pubDate>Thu, 03 Apr 2025 02:10:12 GMT</pubDate>
<description>CannEpil Receives Approval for Prescription in Germany</description>
</item>
<item>
<title>CimetrA Phase IIb Clinical Trial Results</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/cimetra-phase-iib-clinical-trial-results</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/cimetra-phase-iib-clinical-trial-results</guid>
<pubDate>Mon, 17 Mar 2025 01:42:27 GMT</pubDate>
<description>CimetrA Phase IIb Clinical Trial Results</description>
</item>
<item>
<title>Argent BioPharma Expands Pipeline with Promising Drug CimetrA®</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/argent-biopharma-expands-pipeline-promising-220000037</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/argent-biopharma-expands-pipeline-promising-220000037</guid>
<pubDate>Sun, 16 Mar 2025 22:00:00 GMT</pubDate>
<description>Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COV</description>
</item>
<item>
<title>Strategic Manufacturing Partnership with ECCPharm Limited</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/strategic-manufacturing-partnership-with-eccpharm-limited</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/strategic-manufacturing-partnership-with-eccpharm-limited</guid>
<pubDate>Wed, 05 Mar 2025 04:14:13 GMT</pubDate>
<description>Strategic Manufacturing Partnership with ECCPharm Limited</description>
</item>
<item>
<title>Half Year Accounts</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/half-year-accounts-139</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/half-year-accounts-139</guid>
<pubDate>Fri, 28 Feb 2025 10:36:07 GMT</pubDate>
<description>Half Year Accounts</description>
</item>
<item>
<title>Placing to Raise US$4,500,000</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/placing-to-raise-usdollar4500000</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/placing-to-raise-usdollar4500000</guid>
<pubDate>Tue, 07 Jan 2025 04:22:12 GMT</pubDate>
<description>Placing to Raise US$4,500,000</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/argent-biopharma-limited/news/trading-halt-1361</link>
<guid isPermaLink="true">https://6ix.com/company/argent-biopharma-limited/news/trading-halt-1361</guid>
<pubDate>Fri, 03 Jan 2025 03:55:06 GMT</pubDate>
<description>Trading Halt</description>
</item>
</channel>
</rss>